EyePoint Pharmaceuticals (EyePoint Pharmaceuticals) Debt-to-Equity : 0.02 (As of Dec. 2023)

View and export this data going back to 2008. Start your Free Trial

What is EyePoint Pharmaceuticals Debt-to-Equity?

EyePoint Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. EyePoint Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.91 Mil. EyePoint Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $266.32 Mil. EyePoint Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 0.02.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for EyePoint Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

EYPT' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.98 Max: 6.02
Current: 0.02

During the past 13 years, the highest Debt-to-Equity Ratio of EyePoint Pharmaceuticals was 6.02. The lowest was 0.02. And the median was 0.98.

EYPT's Debt-to-Equity is ranked better than
88.01% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs EYPT: 0.02

EyePoint Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for EyePoint Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Debt-to-Equity Chart

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

6.02

2.21

0.21

0.48

0.02

EyePoint Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.48	0.52	0.11	0.11	0.02

Competitive Comparison of EyePoint Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EyePoint Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Debt-to-Equity falls into.

EyePoint Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

EyePoint Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	4.906)	/	266.323
	=	0.02

EyePoint Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	4.906)	/	266.323
	=	0.02

EyePoint Pharmaceuticals (NAS:EYPT) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

EyePoint Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (EyePoint Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (NAS:EYPT) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PV3B:Germany

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

Executives

Ye Liu	director	ROOM 502-I, WANT WANT PLAZA, NO. 211 SHIMEN YI ROAD, SHANGHAI F4 200041
Dario A. Paggiarino	officer: Chief Medical Officer	4025 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
Michael Craig Pine	officer: Chief Corp Dev.&Strat. Officer	C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, SUITE A-210, WATERTOWN MA 02472
Nancy Lurker	director, officer: President and CEO	PDI, INC., 1 ROUTE 17 SOUTH, SADDLE RIVER NJ 07458
Stuart Duty	director	22722 29TH DR SE, SUITE 100, BOTHELL WA 98021
Ew Healthcare Partners, L.p.	10 percent owner	21 WATERWAY AVENUE, SUITE 225, THE WOODLANDS TX 77380
Karen L. Zaderej	director	AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Anthony P Adamis	director	3 TIMES SQUARE, 12TH FLOOR, NEW YORK NY 10036
Therapeutics Ocumension	10 percent owner	56F, ONE MUSEUM PLACE, 669 XIN ZHA ROAD, JING'AN DISTRICT, SHANGHAI F4 200041
George Elston	officer: Chief Financial Officer	124 CHATHAM STREET, CHATHAM NJ 07928
Wendy F Dicicco	director
David Scott Jones	officer: SVP & Chief Commercial Officer	C/O EYEPOINT PHARMACEUTICALS, INC.,, 480 PLEASANT STREET, SUITE A210, WATERTOWN MA 02472
John B. Landis	director	1700 KENT AVENUE, WEST LAFAYETTE IN 46906
Jay S. Duker	director	C/O ELEVEN BIOTHERAPEUTICS, 215 1ST ST. #400, CAMBRIDGE MA 02142
Douglas Evan Godshall	director	SUITE 4 LEVEL 46 2 PARK STREET, SIDNEY C3 2000